MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.
Managing Director Roby Zomer says: "MGC Pharma's research has demonstrated the effect of naturally derived cannabinoid products on stage IV brain tumours without the use of toxic chemotherapy components. We are proud of the work achieved thus far and are looking forward to advancing our proprietary formulation to the next stage of clinical trials."
The National Institute of Biology is the largest independent Public Research Institution for Life Sciences in Slovenia.
Current stock price: up 17% at 1.08 pence on Thursday
12-month change: down 59%
By Xindi Wei; xindiwei@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.